Silverarc Capital Management’s Avidity Biosciences RNAM Stock Holding History

Silverarc Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-844,633	Closed	-$36.8M	–	93
2025 Q3	$36.8M	Buy	844,633 +434,633	+106%	+$17.6M	4.96%	3
2025 Q2	$11.6M	Sell	410,000 -1,312	-0.3%	-$39.1K	2.15%	19
2025 Q1	$12.1M	Sell	411,312 -132,339	-24%	-$4.12M	2.48%	11
2024 Q4	$15.8M	Buy	543,651 +68,096	+14%	+$2.85M	3.46%	10
2024 Q3	$21.8M	Sell	475,555 -42,179	-8%	-$1.83M	4.91%	4
2024 Q2	$21.1M	Buy	517,734 +28,431	+6%	+$816K	4.99%	3
2024 Q1	$12.5M	Buy	+489,303	New	+$7.67M	3.47%	7
2023 Q1	–	Sell	-128,000	Closed	-$2.84M	–	100
2022 Q4	$2.84M	Buy	+128,000	New	+$1.91M	0.81%	42

Other funds holding RNAM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Silverarc Capital Management's RNAM Position: Q4 2025 in Review

Silverarc Capital Management sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 844,633 shares — an estimated $36.8M sold.

Silverarc Capital Management first reported a position in RNAM in Q4 2022 and held it in 8 quarters. The position peaked at $36.8M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

Silverarc Capital Management reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
Silverarc Capital Management sold 844,633 Avidity Biosciences shares in Q4 2025, an estimated $36.8M.
Silverarc Capital Management first reported a position in Avidity Biosciences in Q4 2022 and held it in 8 quarters.
Silverarc Capital Management's Avidity Biosciences position peaked at $36.8M in Q3 2025.
343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.